3r4o
From Proteopedia
(Difference between revisions)
												
			
			| Line 1: | Line 1: | ||
| + | |||
| ==Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide== | ==Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide== | ||
| <StructureSection load='3r4o' size='340' side='right' caption='[[3r4o]], [[Resolution|resolution]] 2.65Å' scene=''> | <StructureSection load='3r4o' size='340' side='right' caption='[[3r4o]], [[Resolution|resolution]] 2.65Å' scene=''> | ||
| == Structural highlights == | == Structural highlights == | ||
| - | <table><tr><td colspan='2'>[[3r4o]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/ | + | <table><tr><td colspan='2'>[[3r4o]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3R4O OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3R4O FirstGlance]. <br> | 
| </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=FU3:2-AMINO-N-CYCLOBUTYL-4-[2,4-DICHLORO-6-(4,4,4-TRIFLUOROBUTOXY)PHENYL]-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE'>FU3</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=FU3:2-AMINO-N-CYCLOBUTYL-4-[2,4-DICHLORO-6-(4,4,4-TRIFLUOROBUTOXY)PHENYL]-5,7-DIHYDRO-6H-PYRROLO[3,4-D]PYRIMIDINE-6-CARBOXAMIDE'>FU3</scene></td></tr> | ||
| <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3r4m|3r4m]], [[3r4n|3r4n]], [[3r4p|3r4p]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[3r4m|3r4m]], [[3r4n|3r4n]], [[3r4p|3r4p]]</td></tr> | ||
| - | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">HSP90AA1, HSP90A, HSPC1, HSPCA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606  | + | <tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">HSP90AA1, HSP90A, HSPC1, HSPCA ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr> | 
| - | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3r4o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r4o OCA], [http://www.rcsb.org/pdb/explore.do?structureId=3r4o RCSB], [http://www.ebi.ac.uk/pdbsum/3r4o PDBsum]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=3r4o FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3r4o OCA], [http://pdbe.org/3r4o PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=3r4o RCSB], [http://www.ebi.ac.uk/pdbsum/3r4o PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=3r4o ProSAT]</span></td></tr> | 
| </table> | </table> | ||
| == Function == | == Function == | ||
| Line 18: | Line 19: | ||
| From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
| </div> | </div> | ||
| + | <div class="pdbe-citations 3r4o" style="background-color:#fffaf0;"></div> | ||
| ==See Also== | ==See Also== | ||
| Line 25: | Line 27: | ||
| __TOC__ | __TOC__ | ||
| </StructureSection> | </StructureSection> | ||
| - | [[Category:  | + | [[Category: Human]] | 
| [[Category: Gajiwala, K S]] | [[Category: Gajiwala, K S]] | ||
| [[Category: Atp binding]] | [[Category: Atp binding]] | ||
| [[Category: Chaperone]] | [[Category: Chaperone]] | ||
| [[Category: Chaperone-chaperone inhibitor complex]] | [[Category: Chaperone-chaperone inhibitor complex]] | ||
Revision as of 16:02, 4 August 2016
Optimization of Potent, Selective, and Orally Bioavailable Pyrrolodinopyrimidine-containing Inhibitors of Heat Shock Protein 90. Identification of Development Candidate 2-amino-4-{4-chloro-2-[2-(4-fluoro-1H-pyrazol-1-yl)ethoxy]-6-methylphenyl}-N-(2,2-difluoropropyl)-5,7-dihydro-6H-pyrrolo[3,4-d]pyrimidine-6-carboxamide
| 
 | |||||||||||
